Stephen P Mulligan

19PUBLICATIONS
85CO-AUTHORS
Haematological tumoursLanguage documentation and descriptionCancer therapy (excl. chemotherapy and radiation therapy)NanomedicineRespiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Sep 20, 2026
Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.

|Jul 07, 2026
Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

|Feb 26, 2026
Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia.

Raúl Córdoba, Stephan Stilgenbauer, Paolo Ghia

|Jul 27, 2025
Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.

Stephen P Mulligan, Philip A Thompson, Joel Wight

|Feb 05, 2024
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.

Constantine S Tam, Stephen Opat, Shirley D'Sa

|Nov 11, 2023
Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemia.

Ross Salvaris, Stephen Mulligan, Andrea Puig

Pageof 4

Frequent Collaborators

5 joint publications

Stephen Opat

5 joint publications

Constantine Si Lun Tam

4 joint publications

Yandong Shen

3 joint publications

Andrea Puig